Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Elizabeth Jimenez Aguilar"'
Autor:
Jose María Mazarico, Vicente Alfaro, Luis Paz-Ares, Elizabeth Jimenez-Aguilar, Javier Baena, Ali Zeaiter, Carmen Kahatt, Andrea Modrego
Publikováno v:
Future Oncology. 17:2279-2289
Lurbinectedin is a marine-derived drug that inhibits transcription, a process that is frequently dysregulated in small cell lung cancer. The activity of lurbinectedin has been studied in many solid tumors, showing not only promising results but also
Autor:
Pasi A. Jänne, Renato Umeton, Andrew Polio, Elizabeth Jimenez Aguilar, Giuseppe Lamberti, Joao Victor Machado Alessi, Lynette M. Sholl, Gonzalo Recondo, Natalie I. Vokes, Navin R. Mahadevan, Giulia Costanza Leonardi, Marissa N. Lawrence, Biagio Ricciuti, Eliezer M. Van Allen, Mark M. Awad
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background High tumor mutational burden (TMB) and PD-L1 expression are associated with improved clinical outcomes in patients (pts) with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, how TMB performs as
Autor:
Andrew J. Plodkowski, Jia Luo, Biagio Ricciuti, Joao Victor Machado Alessi, Zihan Wei, Matthew D. Hellmann, Hira Rizvi, Mizuki Nishino, Mehmet Altan, Peter Sawan, Brett W. Carter, John V. Heymach, Mark M. Awad, Fangxin Hong, Elizabeth Jimenez-Aguilar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPatients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-
Autor:
David Liu, Renato Umeton, Hira Rizvi, Pasi A. Jänne, Mizuki Nishino, Ahmet Zehir, Claire A. Margolis, Felix Dietlein, Biagio Ricciuti, Meng Xiao He, Francisco Sanchez-Vega, Eliezer M. Van Allen, Lynette M. Sholl, Nikolaus Schultz, Jeffrey Girshman, Elizabeth Jimenez-Aguilar, Anika E. Adeni, Haitham Elmarakeby, Suzanne E. Dahlberg, Natalie I. Vokes, Matthew D. Hellmann, Mark M. Awad
Publikováno v:
JCO precision oncology. 3
PURPOSE Heterogeneity in tumor mutational burden (TMB) quantification across sequencing platforms limits the application and further study of this potential biomarker of response to immune checkpoint inhibitors (ICIs). We hypothesized that harmonizat
Autor:
John V. Heymach, Michael E. Goldberg, Niamh Long, Darragh Halpenny, Neelesh Sharma, William J. Geese, Jennifer L. Sauter, David R. Spigel, Ignacio I. Wistuba, Gaurav Singal, Jose A. Bufill, Alexa B. Schrock, Andrew J. Plodkowski, Roxana Azimi, Jaime Rodriguez-Canales, Neda Kalhor, Lee A. Albacker, Pan Tong, Mari Mino-Kenudson, Joseph D. Szustakowski, Elizabeth Jimenez Aguilar, Pamela Villalobos, Lynette M. Sholl, Ryan J. Hartmaier, Edwin Roger Parra, Robin Edwards, Mizuki Nishino, Patrik Vitazka, Vincent A. Miller, Jing Wang, Yasir Elamin, Charles M. Rudin, Brett W. Carter, Jeremy J. Erasmus, Warren Denning, Ariella Sasson, David Fabrizio, Matthew D. Hellmann, Philip J. Stephens, Giulia Costanza Leonardi, Sujaya Srinivasan, Julia A. Elvin, Sally E. Trabucco, Jeffrey S. Ross, Alice T. Shaw, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Nir Peled, Stefan Kirov, Danielle Greenawalt, Taghreed Hirz, Pasi A. Jänne, Siraj M. Ali, Jedd D. Wolchok, Ferdinandos Skoulidis, Péter Szabó, Kwok-Kin Wong, Jianjun Zhang, Haifa Hamdi, Justin F. Gainor, Garrett M. Frampton, Sai-Hong Ignatius Ou, Mark M. Awad, Hira Rizvi, Fei Jiang, Han Chang, Achim A. Jungbluth, Ana Galan-Cobo
Publikováno v:
Cancer Discovery. 8:822-835
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subg
Autor:
Carmen Kahatt, Luis Paz-Ares, Inmaculada Sanchez-Simon, Elizabeth Jimenez Aguilar, Rafael Nuñez, Santiago Ponce Aix, Sonia Extremera, Alejandro Falcon Gonzalez, Jesus R Fernandez, Elena Brehcist, Julia Martinez, Ali Zeaiter, Gregory M. Cote
Publikováno v:
Journal of Clinical Oncology. 39:5586-5586
5586 Background: LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus promptin
Autor:
Elizabeth Jimenez Aguilar, Santiago Ponce Aix, Gregory M. Cote, Eva Maria Gonzalez, Juan Manuel Sepúlveda, Luis Paz-Ares, Mariano Siguero, Ali Zeaiter, Monica Insa, Inmaculada Sanchez-Simon, Maria Jose Flor, Rafael Nuñez, Martin Cullell-Young, Alejandro Gonzalez, Carmen Kahatt
Publikováno v:
Journal of Clinical Oncology. 38:3514-3514
3514 Background: LUR is a novel agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus prompt
Autor:
Mark Awad, Navin R. Mahadevan, Andrew Polio, Elizabeth Jimenez Aguilar, Natalie I Vokes, Biagio Ricciuti, Giulia C Leonardi, Christine A Lydon, Anika E Adeni, Pasi A Jänne, Eliezer M Van Allen, Adem Albayrak, Renato Umeton, Lynette M Sholl
Publikováno v:
SSRN Electronic Journal.
Autor:
Mark M. Awad, S. Subegdjo, Christine A. Lydon, Sasha Kravets, Matthew D. Hellmann, Elizabeth Jimenez Aguilar, Hira Rizvi, Anika E. Adeni
Publikováno v:
Journal of Clinical Oncology. 36:9037-9037
9037Background: Among patients with NSCLC and a PD-L1 TPS ≥50%, the response rate to the PD-1 inhibitor pembrolizumab is ~45%. Whether certain subsets of patients with a PD-L1 TPS ≥50% are more lik...
Autor:
Danyon Anderson, Justin F. Gainor, Alice T. Shaw, Hira Rizvi, Mark M. Awad, Elizabeth Jimenez Aguilar, Megan Tenet, Mari Mino-Kenudson, Meghan J. Mooradian, Matthew D. Hellmann, Jennifer L. Sauter, Christine A. Lydon
Publikováno v:
Journal of Clinical Oncology. 36:9011-9011
9011Background: PD-1 blockade is now standard first-line therapy for patients (pts) with advanced NSCLC and a PD-L1 tumor proportion score (TPS) ≥50%. Tumor mutation burden (TMB) is also a biomarke...